"Where do you see the most growth in the field of ophthalmology?"
Dr. McDonnell anticipated the specialty as a whole would need to adapt to provide more efficient care, to more people, at lower costs.
He wrote about the increasing pressures put on ophthalmologists in a recent editorial, “Ten-day workweek for ophthalmologists.” In addition, some experts weighed in about how to best prevent ophthalmic burnout.
Dr. Olson anticipated the approval of the Tecnis Symfony IOL (Abbott) and Light Adjustable Lens IOL (Calhoun Vision), which he said would be game changers in the refractive premium IOL market. Indeed, the big IOL news of the year was approval of the Symfony IOL as the first extended-depth-of-focus IOL.
Molecular genetics, small molecules as drug delivery targets, and nanotechnology were the areas Dr. Lee anticipated major advances in during the year. This year, positive results were observed from a phase I trial of voretigene neparvovec to treat a gene mutation in patients with retinal dystrophy.